Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Histone Methyltransferase
    (1)
  • Proteasome
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

a 924

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Inhibitors_Agonists
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
A 924
A924,A-924
T2645965132-74-3
A 924 is an amino acid derivative with antineoplastic activity.
  • $1,520
6-8 weeks
Size
QTY
PR-924
T165681416709-79-9
PR-924 is a selective inhibitor of tripeptide epoxyketone immunoproteasome subunit LMP-7 (IC50: 22 nM). PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities. PR-924 covalently modifies proteasomal N-terminal threonine active sites.
  • $722
5 days
Size
QTY
CI 924
EINECS 279-174-7,CI-924,CI924
T3091779520-77-7
CI 924 is a lipid-lowering drug. CI 924 increased anti-atherosclerotic HDL and decreased VLDL at 600 mg/day.
  • $1,520
6-8 weeks
Size
QTY
Zetomipzomib
T374191629677-75-3
KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential for the research of multiple autoimmune diseases[1][2]. KZR-616 also inhibits MECL-1 subunit (IC50=623 nM) and constitutive proteasome β5 subunit (IC50=688 nM). KZR-616 maintains LMP7 and LMP2 selective inhibition in MOLT-4 cells. KZR-616 (250 nM) shows a comparable cytokine inhibition profile peripheral blood mononuclear cells (PBMC)[1].KZR-616 is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914 and PR-924 [3]. KZR-616 (5 mg/kg; i.v.; dosing was repeated on days 6, 8, 11, and 13) shows efficacy in the anticollagen antibody induced arthritis (CAIA) model[1]. [1]. Johnson HWB, et al. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem. 2018 Dec 27;61(24):11127-11143. [2]. Muchamuel T, et al. FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases 2018;77:685. [3]. Xi J, et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646.
  • $8,450
10-14 weeks
Size
QTY
Ethyl 3-(dimethylamino)acrylate
T66876924-99-2
Ethyl 3-(dimethylamino)acrylate is a useful organic compound for research related to life sciences. The catalog number is T66876 and the CAS number is 924-99-2.
    7-10 days
    Inquiry
    ZZM-1220
    T79776
    ZZM-1220, a covalent inhibitor of histone lysine methyltransferase G9a GLP, exhibits IC50 values of 458 nM for G9a and 924 nM for GLP. It effectively inhibits H3K9me2 in cells, induces apoptosis in triple-negative breast cancer (TNBC) cells, and arrests the cell cycle at the G2 M phase [1].
    • Inquiry Price
    Size
    QTY
    N-Nitroso-Di-n-Butylamine-d18
    TMIJ-03501219798-82-9
    N-Nitroso-Di-n-Butylamine-d18 is a deuterated compound of N-Nitroso-Di-n-Butylamine. N-Nitroso-Di-n-Butylamine has a CAS number of 924-16-3.
    • Inquiry Price
    20 days
    Size
    QTY